Track topics on Twitter Track topics that are important to you
Zogenix announced on Thursday (July 12) that its Phase 3 trial of ZX008 in Dravet syndrome met its primary and secondary endpoints, putting both regulatory submissions for the drug’s approval on pace for Q4 2018.
The post Zogenix’s Phase 3 Clinical Study Met all Endpoints appeared first on Investing News Network.
Original Article: Zogenix’s Phase 3 Clinical Study Met all EndpointsNEXT ARTICLE
Clinical Approvals Clinical Trials Drug Approvals Drug Delivery Drug Discovery Generics Drugs Prescription Drugs In the fields of medicine, biotechnology and pharmacology, drug discovery is the process by which drugs are dis...